热门资讯> 正文

埃斯珀解决与雷迪博士关于胆固醇药物的专利纠纷

2025-10-03 22:49

Esperion Therapeutics (NASDAQ:ESPR) announced it has reached a settlement with Dr. Reddy’s Laboratories (NYSE:RDY) regarding the latter’s bid to launch generic versions of NEXLETOL and NEXLIZET in the U.S.
Under the agreement, Dr. Reddy’s will not market generic versions of the two cholesterol-lowering drugs before April 19, 2040, when the relevant patents expire.
Esperion noted that patent litigation with other defendants over the same products remains ongoing.

More on Esperion Therapeutics, Dr. Reddy's

Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now
Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript
Esperion Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation
SA Asks: How could higher India tariffs impact drug stocks?
Esperion rises after revenue beat, Q1 profitability expectation

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。